Evidence map›Paper›PMID 35667092›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Presurgery Adhesion Molecules and Angiogenesis Biomarkers Are Differently Associated with Outcomes in Colon and Rectal Cancer: Results from the ColoCare Study.

Jennifer Ose, Biljana Gigic, Sheetal Hardikar, Tengda Lin, Caroline Himbert, Christy A Warby, Anita R Peoples, Clara L Lindley, Juergen Boehm, Petra Schrotz-King and 8 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Pre-Surgery Inflammatory and Angiogenesis Biomarkers as Predictors of 12-Month Cancer-Related Distress: Results from the ColoCare Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  11. Associations of Individual and Combined Physical Activity and Body Mass Index Groups with Proinflammatory Biomarkers among Colorectal Cancer Patients.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Jennifer OseUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-2030-9676
Biljana GigicUniversity Hospital Heidelberg, Germany.ORCID 0000-0002-8085-2072
Sheetal HardikarUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-0292-6168
Tengda LinUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0001-5147-8432
Caroline HimbertUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-4084-8340
Christy A WarbyHuntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0003-1772-8332
Anita R PeoplesUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-3645-3960
Clara L LindleyUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0001-6156-254X
Juergen BoehmHuntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0001-8639-3543
Petra Schrotz-KingDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4339-3492
Jane C FigueiredoCedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-8040-3341
Adetunji T ToriolaWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-1079-2606
Erin M SiegelH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0003-1779-2510
Christopher I LiFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-1543-0743
Alexis UlrichLukaskrankenhaus Neuss, Neuss, Germany.ORCID 0000-0003-1469-2186
Martin SchneiderUniversity Hospital Heidelberg, Germany.ORCID 0000-0001-8215-7359
David ShibataUniversity of Tennessee Health Science Center, Memphis, Tennessee.ORCID 0000-0002-5670-423X
Cornelia M UlrichUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0001-7641-059X
University of Utah · USHeidelberg University · DEHuntsman Cancer Institute · USCedars-Sinai Medical Center · USFred Hutch Cancer Center · USLukaskrankenhaus · DEMoffitt Cancer Center · USUniversity of Tennessee Health Science Center · USWashington University in St. Louis · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jennifer Anne Doherty · 1986 to 2026
$72.6M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP StudyR01CA211705 · NCI · UNIVERSITY OF UTAH · PI LASTAYO, PAUL C, ULRICH, CORNELIA M · 2017 to 2021
$2.2M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
Global metabolomics profiling, dietary factors, and colorectal cancer risk in the NIH-Consortium of Metabolomics Studies (COMETS)R03CA270473 · NCI · UNIVERSITY OF UTAH · PI PLAYDON, MARY CHRISTINE · 2022 to 2023
$151k
NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA211705NCI NIH HHS R01 CA254108NCI NIH HHS R03 CA270473NCI NIH HHS U01 CA206110
6 · The paper itself

Abstract

backgroundCell-to-cell adhesion and angiogenesis are hallmarks of cancer. No studies have examined associations of adhesion molecules and angiogenesis biomarkers with clinical outcomes in colorectal cancer.

methodsIn presurgery serum from n = 426 patients with colorectal cancer (stage I-III), we investigated associations of CRP, SAA, adhesion molecules (sICAM-1, sVCAM-1), and angiogenesis markers (VEGF-A and VEGF-D) with overall survival (OS), disease-free survival (DFS), and risk of recurrence. We computed HRs and 95% confidence intervals; adjusted for age, sex, BMI, stage, site, and study site, stratified by tumor site in exploratory analyses.

resultsN = 65 (15%) were deceased, and 39 patients (14%) had a recurrence after a median follow-up of 31 months. We observed significant associations of biomarkers with OS, DFS, and risk of recurrence on a continuous scale and comparing top to bottom tertile, with HRs ranging between 1.19 and 13.92. CRP was associated with risk of death and recurrence in patients in the top tertile compared with patients in the bottom tertile, for example, risk of recurrence HRQ3-Q1: 13.92 (1.72-112.56). Significant heterogeneity between biomarkers and clinical outcomes was observed in stratified analysis by tumor site for CRP, SAA, sICAM-1, sVCAM-1, and VEGF-D. VEGF-D was associated with a 3-fold increase in risk of death for rectal cancer (HRlog2: 3.26; 95% CI, 1.58-6.70) compared with no association for colon cancer (HRlog2: 0.78; 95% CI, 0.35-1.73; Pheterogenity = 0.01).

conclusionsAdhesion molecules and angiogenesis biomarkers are independent prognostic markers for colorectal cancer, with differences by tumor site. IMPACT: There is need for tailored treatment for colon and rectal cancer.

Indexed as

Cell Adhesion MoleculesNeovascularization, PathologicRectal NeoplasmsBiomarkersColonHumansPrognosisVascular Endothelial Growth Factor DBiomarkersCell Adhesion MoleculesVascular Endothelial Growth Factor D

Identifiers

PMID35667092
PMCPMC9509698
OpenAlexW4282935106

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.